A Norwegian case–control study examined first-trimester pregnancies in 13,956 women from registry data and found no evidence of an increased risk for early pregnancy loss after Covid-19 vaccination.
In the 28-day, 2,052 patient, Phase III, PREPARE-IT 2 trial (NCT04460651), treatment with icosapent ethyl did not reduce hospitalization or death compared to placebo (13.69% vs 11.16%) in nonhospitalized Argentinian COVID-19 patients.
AZ announced that after six months 4,991 patients enrolled in the PROVENT trial, no cases of severe COVID-19 or COVID-19-related death occurred in patients that received AZD7442 compared to five cases of severe COVID-19 and two COVID-related deaths with placebo.
In the 15-day, 511 patient, Phase III, C3PO trial (NCT04355767 treatment with convalescent plasma did not reduce emergency treatment, hospitalization or death in high-risk outpatients with COVID-19.
In the 29-day, 583 patient, Phase III, COMET-ICE trial (NCT04545060), 1% of patients treated with sotrovimab
were hospitalized or died compared to placebo in outpatients with COVID-19 who were at high risk of progression to severe disease.
Stay informed, subscribe to the Prescribe Right Pharmaceutical Pipeline Tracker